Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00499200 | Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy | PHASE1 | COMPLETED | 42 | — | — | Oct 1, 2007 | Jun 1, 2008 | Jul 9, 2008 | 1 | Sweden |
| Arm | Type | Description |
|---|---|---|
| SRA-444 + Placebo | EXPERIMENTAL | Experimental; Placebo |
| Name | Type | Description |
|---|---|---|
| SRA-444 | DRUG | - |
Inclusion criteria: * Men or women from 60 years of age at screening. * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion criteria: * History of drug abuse ...